Recent large-scale epidemiological studies have documented a strong association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). This observation has two important scientific and clinical aspects: (i) to reveal the pathomechanism linking LUTS and ED and (ii) to consider this fact in the individual approach for diagnosis and management of these two disorders. The following hypotheses are under investigation to explain the relation between LUTS and ED: (i) an increased Rho-kinase activation, (ii) an a-adrenergic receptor imbalance, (iii) a decrease of NOS/ NO in the endothelium, (iv) atherosclerosis affecting the small pelvis and (v) an autonomic hyperactivity, each affecting simultaneously bladder, prostate and penis. According to a recent randomized trial, sildenafil has a positive effect on LUTS yet not on uroflowmetry in men with LUTS and ED. Although further trials are mandatory, phosphodiesterase-5 inhibitors might play a role in the management of LUTS in the future. a-Blockers have no relevant effect on erectile function, tamsulosin leads to retrograde ejaculation in up to 10%. 5a-Reductase inhibitors are associated with ED, loss of libido and reduction of ejaculate volume in up to 10%. Transurethral and open prostatectomy induce retrograde ejaculation in up to 90% of patients while their impact on erectile function is still controversially discussed. Minimal invasive treatment options (laser prostatectomy, transurethral microwave thermotherapy) have a lower rate of retrograde ejaculation in the range of 20-70%. LUTS and ED are strongly linked although the exact mechanism is poorly understood. Men seeking for help for LUTS/benign prostatic hyperplasia should be assessed for different aspects of sexual dysfunction and informed regarding the impact of medication and surgery on sexual health.
Introduction
Until recently, the association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) has been attributed to the underlying bias age. This is emphasized by the fact that in the vast majority of reviews and guidelines on ED, LUTS were not considered as an independent risk factor. 1, 2 In fact, both entities belong to the most frequent urologic disorders 3, 4 and a variety of recent large-scale epidemiological studies analysing 1200-12 000 men have convincingly documented an age-independent relationship between LUTS and ED leading to a new paradigm in the fields of research, diagnosis and treatment. [5] [6] [7] [8] [9] [10] [11] [12] [13] Despite the fact that the underlying pathophysiology is still poorly understood, several theories have been elaborated to link both disorders, such as the Rho-kinase pathway, a-adrenergic receptor imbalance, a decrease of NOS/NO in the endothelium, atherosclerosis and an autonomic hyperactivity. From the clinical standpoint the most important issue is the impact of surgical and medical treatment for LUTS on male sexual function. An emerging and highly interesting aspect is the positive impact of phosphodiesterase (PDE)-5-inhibitors on LUTS.
Epidemiology
The first large-scale study reporting on an ageindependent association between LUTS and male sexual dysfunction was presented by Lukacs et al. in 1999. 14 According to this analysis of 5849 men who underwent a 1-year observational trial with alfuzosin, baseline LUTS were strongly correlated to different aspects of sexual dysfunction. The only drawback of this analysis was the lack of a validated questionnaire to assess ED. 14 Meanwhile, more than a dozen papers confirmed the relationship between LUTS and ED, the majority of those published in the last 5 years, comprising more than 35 000 men with an average increase of 100% for ED in the case of moderate to severe LUTS ( Table 1) .
The largest study available is the multinational survey of the aging male (MSAM-7) by Rosen et al. 7 investigating the relationship between LUTS and various aspects of sexuality by validated instruments. Additionally, this study provided evidence for the impact of LUTS on ejaculation and hypoactive desire disorder. In this mailed survey 12 815 men aged 50-80 years in the United States of America and six European countries were analysed. Thirty-one percent of respondents had moderate to severe LUTS and 48.7% reported on difficulties achieving an erection; 10% reported on a complete absence of erection. Within each age category, the frequency of ED was strongly related to severity of LUTS with a relative risk (RR) increasing from 3.1 (moderate LUTS) to 5.9 (severe LUTS) regardless of the coexistence of diabetes, hypertension, cardiac disease or hyperlipidemia. 7 Our group has investigated the association between LUTS (IPSS) and ED (International Index of Erectile Function; IIEF-5) in 2858 men by controlling for age and co-morbidity as determined by a standardized, detailed health investigation guided by a general practitioner. 11 We calculated a RR for ED in men with LUTS (IPSS47) of 2.2. This association was observed independently of age, vascular risk factors and the predominance of obstructive or irritative symptoms.
The only study to date investigating the impact of LUTS on the incidence of ED was reported by Shiri et al. 13 In this cohort of 1126 men aged 50-70 years residing in Tampere, Finland, they observed a RR for ED incidence of 2.7 in men with a baseline DAN-PSS between 7 and 11 and a RR of 3.1 in those with a DAN-PSS412 over a period of 5 years. The incidence of ED increased by 5% for each 1-point increment in LUTS score. 13 To look beyond male sexual dysfunction, Hansen 10 investigated the association between LUTS and sexual function in both sexes by a mailed survey of a random sample of 15 000 men and women between 40 and 65 years in Denmark. LUTS were assessed by the IPSS and sexual function by the DAN-PSS (men) and the Pelvic Organ ProlapseUrinary Incontinence Sexual Function Questionnaire (women). LUTS increased the RR for sexual dysfunction with a factor of 2.07 for voiding symptoms, 1.55 for storage symptoms and 2.82 for mixed LUTS in men. The corresponding figures for women were 1.75, 1.47 and 2.77.
Despite these reproducible and convincing data one has to be aware that a relationship between two entities cannot be established on the basis of epidemiological data only but can be assumed applying Hill's criterion. Indeed, according to Hill's epidemiological method -considering strength of association, internal consistency and dose-response effects -a causal link between LUTS and ED has to be strongly proposed. 15 
Hypotheses for a causal relationship between LUTS and ED
The question now arises, whether LUTS have a direct impact on male sexual function or whether both disorders are linked by a common underlying mechanism; an impact of ED on LUTS, on the other hand, seems rather unlikely.
Several hypotheses have been elaborated to explain the association between LUTS and ED.
(i) The increased Rho-kinase activation -hypothesis proposes decreased smooth muscle relaxation with consecutive increased bladder outlet resistance and impaired erection. 16 It has to be emphasized that a multisystem dysfunction of 
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Rho-kinase has -as all of the following hypotheses -only an experimental basis.
(ii) An a-adrenergic receptor imbalance/dysregulation, 17 as a-adrenergic receptor upregulation is known to play a crucial role in mediating LUTS by increasing bladder neck and prostate tone.
(iii) An impaired nitric oxidase synthase (NOS) in the endothelium of the pelvis including prostate, bladder and penis. 18 This concept derives from experimental data describing reduced NOS production in the transition zone of the prostate in benign prostatic hyperplasia (BPH) and links this model with the known role of NO as the first messenger in smooth muscle relaxation in the corpora cavernosa of the penis during erection. According to this theory, decreased NOS activity in BPH tissue results in altered prostatic tone and subsequently contributing to the dynamic aspect of LUTS. In this hypothesis, which is based on a limited number of experimental animal model studies, vascular risk factors such as diabetes, hypertension and hyperlipidemia are the predisposing factors for NOS reduction in the prostate, bladder and penis. Owing to the characterization of phosphodiesterase in the human prostate (most common PDE-type 4 and 5), this model also may explain the observation of LUTS improvement during ED therapy using PDE-5 inhibitors. 19 (iv) Atherosclerosis affects the small pelvis resulting in chronic ischaemia of the bladder, prostate and penis. 20 This has to be seen as a result of long-term existence of an unfavourable vascular risk factorprofile (diabetes, hypertension, hyperlipidemia and nicotine abuse), which is known to have a significant impact on the genesis of ED and also may cause structural and functional impairment of lower urinary tract function. In a recent analysis of 1724 men with a mean age of 52.3 years, those with more than one major vascular risk factor had a significantly increased IPSS ( þ 24.2%), suggesting an impact of predisposing factors of atherosclerosis on the bladder and lower urinary tract. 21 This theory was also tested in animal models mimicking hypercholesterinemia and pelvic arterial stenosis to induce increased bladder outlet resistance due to smooth muscle loss with loss of compliance. 22 Furthermore, noradrenaline is involved in the contraction of penile tissue via activation of a-adrenergic receptors. 23 (v) Autonomic hyperactivity with sympathetic dysregulation. 24 In the rat model, the autonomic nervous system showed an influence on prostate growth, 25 its antagonizing effect on penile erection is known since decades. 1 As a trigger for the autonomic hyperactivity, the metabolic syndrome represents a plausible mechanism due to its established impact on ED and its possible role in the genesis of LUTS. 22, 26 The last three theories are compatible as chronic ischaemia due to atherosclerosis of the small pelvis may induce autonomic nervous dysregulation, reduced NOS expression and upregulation of Rho kinase with lifestyle as a potentially modifiable key factor in the genesis of LUTS and ED (Figure 1 ).
Impact of ED treatment on the lower urinary tract
The first report on a relevant effect of PDE-5 inhibitors on LUTS was published by Sairam et al. LUTS and ED links for diagnosis, management and treatment A Ponholzer and S Madersbacher sexual intercourse or once daily before bedtime in case of no sexual activity. At the 3-month interval, all men with initially severe LUTS (6%) turned to moderate LUTS and 60% of those with initially moderate LUTS (26%) turned to mild LUTS. IPSS decreased during therapy but this was not shown to be a significant improvement, may be due to the small sample size of this uncontrolled study. A second publication elucidating the effect of a PDE-5-inhibitor on the lower urinary tract was reported by Mulhall et al. 27 on 48 men with a mean age of 62 years. These men had a baseline IPSS410 and received sildenafil because of ED for 3 months. The mean improvement in the IIEF score was 7 points (P ¼ 0.01) and the reduction in the IPSS was 4.6 points (P ¼ 0.013). In total, 60% of men improved their IPSS with 35% showing an atleast 4-point IPSS improvement. Despite the uncontrolled design, these two studies suggested a positive impact of the PDE-5-inhibitor sildenafil on moderate to severe LUTS.
In March 2007, McVary et al. 28 reported on the first placebo-controlled trial on this issue. A total of 369 men with a mean age of 60 years entered this trial. They investigated the effect of 12 weeks of sildenafil in participants presenting with both disorders, ED and LUTS in a 1:1 randomization ratio between sildenafil (50-100 mg/daily) and placebo. Apart from an improvement of the IIEF-EF domain score in the sildenafil group ( þ 9.2 vs þ 1.9 under placebo; Po0.0001), there was also reduction in the IPSS of -6.3 (sildenafil) vs -1.9 in the placebo-group after 12 weeks (Po0.0001). A significant effect on urinary flow or any objective urodynamic parameter was not observed, suggesting a strong impact on psychological well-being in general due to PDE-5-inhibitor effect on erectile function. Data regarding the correlation between LUTS and ED-improvement were not reported. The impact of sildenafil on LUTS, however, outrange current medical treatment options for LUTS and have therefore to be interpreted with caution, in particular as blinding inefficacy might have biased the data. This could explain the significant positive effect of sildenafil on LUTS (IPSS reduction: 6.3) and the low placebo effect (IPSS reduction: 1.9). In most placebo-controlled trials, the placebo induces a much higher reduction of the IPSS (around 4-5 points). 3 Despite these limitations, this randomized trial suggests that men suffering from both disorders -LUTS and ED -may benefit from PDE-5-inhibitors regarding LUTS.
Impact of LUTS/BPH medication on male sexual function
According to current BPH guidelines, recommended medical therapy for moderate to severe, bothersome LUTS due to benign prostatic enlargement (BPE/ benign prostatic obstruction (BPO) comprises a-adrenergic blockers (AB), 5-a-reductase inhibitors (5ARI) and a combination therapy. 3, 29 Each of these approaches has specific yet different aspects on male sexual function and their efficacy has to be balanced against these side effects, in particular in sexually active men. Plant extracts are not elaborated herein because current BPH guidelines do not recommend their use.
a-Adrenergic blockers Alfuzosin, doxazosin, tamsulosin and terazosin are considered as appropriate treatment options for LUTS secondary to BPH with equal clinical effectiveness resulting in an average improvement of 4-6 points in IPSS. 3, 29 Owing to their slightly different receptor affinity to a1-subtypes those four drugs differ in their side-effect profile. As elaborated in the most recent AUA guidelines update a1-blockers lead to ED in 3-5% and a reduced sexual desire by 1-3%; both percentages are very close to the respective placebo levels. Tamsulosin is associated by a higher incidence (10%) of ejaculative disorders than the other a1-blockers (0-1%; placebo level) 29 ( Table 2 ). The incidence of ejaculatory disorders on tamsulosin may increase over time, as shown in long-term extensions of phase III clinical trials. Over a 53-week treatment period, abnormal ejaculation was reported by 10 and 26% of patients with the 0.4 and 0.8 mg doses of tamsulosin, respectively. Over a mean duration of treatment of 64.5 weeks, 30% of patients reported on abnormal ejaculation.
Interestingly, a1-blockers influence ejaculation not by inducing retrograde emission, but mainly via the following two synergistic mechanisms: a peripheral effect of a1-blockers on seminal vesicles and/or the vas deferens and a central effect in the Table 2 Impact of medical BPH therapy on different aspects of male sexual function (%)
Abbreviations: BPH, benign prostatic hyperplasia; CI, confidence interval. Adopted from Carson CC. 31 Bold indicates median.
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control of ejaculation via a high affinity for D2-like and 5HT1A receptors. 30 In conclusion, a1-blockers are associated with a low rate of sexual dysfunction, except of tamsulosin with a higher rate of an ejaculation. Interestingly, treatment in men with concomitant LUTS and sexual dysfunction even was reported to have a positive effect on ED in men receiving alfuzosin in an open 1-year trial. 8, 30, 31 This improvement of erectile function was more pronounced in men with a good response regarding LUTS adding further evidence to the concept of a causal relationship between these two entities.
5-a-Reductase inhibitors
Finasteride and dutasteride are recommended for men with bothersome LUTS and a high risk of disease progression (that is, prostate volume 430-40, high PSA). 5ARIs are the only drugs for BPH currently available that reduce prostate volume by 20-25%. 3, 29 Side-effect profile of 5ARIs is dominated by their impact on sexual health including decreased libido, ED and ejaculatory dysfunction. 3, 29, 32, 33 According to the AUA guidelines, finasteride was associated with an incidence of 8% for ED, 5% for decreased libido and 4% for ejaculatory dysfunction 29 ( Table 2 ). The side effects of dutasteride appear similar to finasteride. In a pooled analysis of three double-blind placebo-controlled studies, which included 4325 men aged 450 years dutasteride was associated with a significantly higher incidence of ED (7.3%), decreased libido (4.2%), gynaecomastia (2.3%) and ejaculatory disorders (2.2%) than was placebo (4.0, 2.1, 0.7 and 0.8%, respectively). Moreover, in a direct comparative study of 1-year duration, dutasteride and finasteride showed comparable incidences of ED (7 vs 8%), decreased libido (5 vs 6%), ejaculatory disorders (1 vs 1%) and gynaecomastia (1 vs 1%). The pathophysiology of increased sexual dysfunction with 5ARIs is still unknown, but might be related to the reduction in DHT.
Combination therapy
The combination of an AB and a 5ARIs is the third recommended treatment option with evidence-based efficacy for the current medical approach to manage LUTS in men with prostatic enlargement. 3, 29 Adverse events reported with the use of combination therapy reflect the combined side effect profile of both drugs, AB and 5aRI. In the well-conducted AUA meta-analysis, rates for ejaculation erection and libido disorders for different combination therapies were calculated (Table 2 ). They ranged between 1 (alfuzosin/finasteride) and 7% (terazosin/ finasteride) for ejaculation disorders, 8 (alfuzosin/ finasteride) and 10% (doxazosin/finasteride) for ED and 2 (alfuzosin/finasteride) and 5% (terazosin/ finasteride) for reduced libido. 31 According to the current largest controlled long-term combination trial, ED (5.1%) decreased libido (2.5%) and abnormal ejaculation (3.1%) belonged to the most frequent adverse events after an observation period of 4.5 years. 34 All aspects of sexual function were decreased compared to the placebo-group (Po0.05) deriving mainly from the side-effect profile of finasteride (all: Po0.05). In the doxacosin cohort, neither ED, nor libido or ejaculation turned out to be significantly reduced from mono-therapy. 34 Furthermore, it seems to be noteworthy to mention that the administration of a PDE-5 inhibitor in addition to any a1-blocker was not reported to induce clinically significant hypotension in treated men and therefore has to be considered to be a safe 'combination'. 35, 36 Impact of BPH surgery on male sexual function Open and transurethral surgery Retrograde ejaculation and ED are the main potential sexual side effects that have to be discussed with the patient before surgery.
Retrograde ejaculation is a well-established side effect of open and transurethral prostatectomy reported by 60-99% of patients with antegrade ejaculation before surgery. Transurethral incision of the prostate (TUIP) has a lower rate of retrograde ejaculation (30-35%) compared to conventional TURP. Therefore, TUIP should be offered to sexually active patients with small-sized prostates (o30 ml).
The impact of BPH-surgery of erectile function is a controversial area, difficult to assess and largely dependent on the patients' perception of sexual activity before surgery as well as on the availability of a sexual partner. This is reflected by the wide range of reported ED rates after surgery ranging from 4 to 50%. The only prospective, randomized trial comparing TURP to watchful waiting did not find that TURP was associated with a higher risk of ED than watchful waiting. 37 Minimally invasive alternative surgical treatment A wide range of minimal invasive treatment options for elderly men with LUTS have been introduced, evaluated and partly abandoned within the past two decades. Currently, the most widely used minimal invasive techniques are transurethral microwave thermotherapy (TUMT), transurethral needle ablation (TUNA) and the KTP laser. In general, few data on the impact of minimal invasive procedures on sexual function are available. The risk of ED after TUMT, TUNA and the KTP Laser is minimal, such as after TURP. Retrograde ejaculation is rarely seen LUTS and ED links for diagnosis, management and treatment A Ponholzer and S Madersbacher after TUMT and TUNA (usually less than 10%). The risk of retrograde ejaculation after the KTP laser ranges from 30 to 75% correlating to the completeness of the laser procedure. If a TUR-like cavity is generated one has to expect a rate of retrograde ejaculation similar to conventional TURP.
Conclusion
Despite the fact that we are currently not able to explain the underlying mechanisms, LUTS and ED are associated independently of age and major co-morbidities. Different hypotheses are under investigation to link these two prevalent disorders including vascular risk factors inducing a variety of processes supposed to affect both, the male lower urinary-and sexual genital tract. The established surgical and medical treatment options for LUTS due to BPE/BPO have a side-effect profile impacting male sexual function that have to be taken into consideration in the individual diagnostic and therapeutic approach. Men seeking help for LUTS should be evaluated regarding ED and those presenting with a sexual disorder as the leading symptom have to be assessed for possible bladder-and prostate dysfunction. An emerging issue is the potential positive effect of PDE-5-inhibitor therapy on LUTS in men with ED and LUTS.
